Skip to content

Change in AP at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$409M+581%
CTO
Citius Oncology, Inc.CTOR
-$1.56M-187%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$2.82M+898%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$2.21M+273%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$3.9M-39.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$219K-45.0%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s change in AP?
TuHURA Biosciences, Inc. (HURA) reported change in AP of $452.01K in Q1 2026.
How has TuHURA Biosciences, Inc.'s change in AP changed year-over-year?
TuHURA Biosciences, Inc.'s change in AP increased by 1.5% year-over-year, from $445.54K to $452.01K.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.